Date: 2016-09-15
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Zymeworks (Canada)
Product: ZW25 - anti-HER2 bispecific antibody
Action
mechanism: bispecific antibody. This bispecific antibody targets two different epitopes of the human epidermal growth factor receptor 2 (HER2) protein, which is over-expressed on the surface of many tumor types, including a subset of breast, gastric, lung, and ovarian cancers. ZW25 is active in numerous in vivo models of HER2 low to high expressing cancers, including ovarian cancer, for which it has received Orphan Drug Designation from the FDA.
Disease: HER2-expressing tumors
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On September 15, 2016, Zymeworks announced that the first patient was dosed in a Phase 1 clinical trial of ZW25 for treatment of HER2-expressing tumors. ZW25 is being evaluated in the clinic for safety, as well as efficacy, in patients with tumors with low to moderate levels of HER2 expression. It has demonstrated an acceptable safety profile in preclinical toxicology studies when administered at multiple dose levels using a once per week dosing schedule.
